Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options. - Wikidata - awgldk - TriplyDB

Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options.

Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options.

http://www.wikidata.org/entity/Q38695599

about

Cytoskeletal Regulation of Inflammation and Its Impact on Skin Blistering Disease Epidermolysis Bullosa Acquisita Mechanisms of Autoantibody-Induced Pathology.Signalling and targeted therapy of inflammatory cells in epidermolysis bullosa acquisita.Clinical features and diagnosis of epidermolysis bullosa acquisita.Toward Clinical use of the IgG Specific Enzymes IdeS and EndoS against Antibody-Mediated Diseases.Autoimmunity and Cytokine Imbalance in Inherited Epidermolysis Bullosa.Nanoparticles prepared from porcine cells support the healing of cutaneous inflammation in mice and wound re-epithelialization in human skin.Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment.T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita.Regulatory T Cells Suppress Inflammation and Blistering in Pemphigoid Diseases.Biomarkers related to bullous pemphigoid activity and outcome.Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.Matrix meets inflammation and DNA repair: Meeting report of the third ADF Round Table.Evidence for a contributory role of a xenogeneic immune response in experimental epidermolysis bullosa acquisita.Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita.Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice.Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients

P2860

Q26740099-F0FD905C-A717-4870-8BA2-F674FEB8E430 Q33740580-7EDA1852-ED88-4156-86E6-5185B6A36A47 Q38749755-68EB8E39-AF9C-49F4-842C-B9DA2C20A9F9 Q38942490-C029C466-AEC9-4146-8E2A-48E20A298CB3 Q40425520-2FBC5CAC-16B2-4757-A15C-DA4ABCBB2FF9 Q41613213-8B2C287C-36F0-49B0-A995-7A32C4060C0A Q41931597-AE6E81E8-116D-469C-80A9-286B7EA7C902 Q42320550-E52883E5-5DDA-4D6D-B366-BD871F5D1235 Q42358830-CAAA41BE-E17E-43B6-80BF-E08FD7BE4E35 Q46244253-EE35D823-FC58-4DE2-85B8-6B01B6B68896 Q47438953-3FBBA37E-FD2B-4674-94D1-D154C67EA4C6 Q47988514-6C2E9FEF-DFA1-4CF1-8EF6-D8713ADFBE30 Q48280201-AC186C0C-FF43-460E-B4F5-837B954DFF21 Q50192333-D525B2E8-60CD-4FAE-A1C8-C121B5D69C91 Q50333828-D0B41FB9-F56A-454B-8D9F-51C2195DBA73 Q52332743-3C140A75-F173-4869-8ECD-435DFDB1D0FC Q58765602-425A7555-F5F4-4CDF-AC60-2F390D8B492C

P2860

Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options.

http://www.wikidata.org/entity/Q38695599

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options.

@en

type

label

Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options.

@en

prefLabel

Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options.

@en

P1433

Q38695599-36023669-F7FB-414C-A648-97C0ED00185A

P1476

Q38695599-D4412FF7-7D1D-42A1-A116-9007122AEA8B

P2093

Q38695599-5B455F56-30BF-432F-86AB-B8F2C38CFD5C

Q38695599-80DEA60C-09B9-4DB7-8FB7-C699E997A31D

Q38695599-913F656A-9CB3-4578-AA69-56C529A60C86

Q38695599-C14FD712-609B-43E6-9330-B1DBA6FC0FDF

Q38695599-E1F16589-B187-402F-8E38-53AA921E463E

P2860

Q38695599-065163DF-AB5F-471A-99FB-AC5AF91CA141

Q38695599-1465AD19-C7D1-4241-825D-67FE4C9783CF

Q38695599-1742C10C-054D-473C-BCD4-EE102E7FB0C3

Q38695599-1851124F-D552-4392-9945-7782953B2D00

Q38695599-1D2249D1-8978-41D4-B633-105E28E47FE3

Q38695599-1FA6C196-C539-420E-8706-8C1C4B355A3C

Q38695599-2385B2B0-EC31-4308-90D6-4839C7FA062E

Q38695599-28D1B02A-8A06-4F65-8231-76C0192122A8

Q38695599-2A3A9BDB-7FFA-4555-B3E0-D568B5AF8CB0

Q38695599-337BEF29-56CE-45D3-A97B-3550B7B8EFC4

P2888

Q38695599-A21B1845-C081-43A9-A954-48AA0BCA0527

P304

Q38695599-E9BA96FE-8A12-4675-A62B-5A8F98C9FD77

P31

Q38695599-3272312C-53F0-4099-84A8-C78A2D2DABA6

P356

Q38695599-610DF59C-1355-4221-BD36-F20995E6081A

P407

Q38695599-7F21136D-222C-4E6C-9853-24F40055ACF3

P433

Q38695599-08756C53-77DB-40EC-AE45-01C5E0AA8724

P478

Q38695599-D0C4DF8F-1568-403B-8E3C-7C21C31FEE1D

P50

Q38695599-26D6642A-32F0-4BE3-8D61-2BA1BF53DC1B

Q38695599-566F0EDF-8FA8-4EC9-9D76-D04F0F43A434

Q38695599-D0BECB70-6EC2-41F2-B658-B5DFDD684E35

P577

Q38695599-C5D3EF31-7A71-4A5A-A370-DD6F4ABCB0F7

P6179

Q38695599-9CD1F510-B170-4B4A-B511-AB7449DC6094

P698

Q38695599-DBFCF861-65CB-4F2A-BE62-A425DEB63329

P356

P1433

Journal of Investigative Dermatology

P1476

Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options

@en

P2093

Christian D Sadik

http://www.w3.org/2001/XMLSchema#string

Detlef Zillikens

http://www.w3.org/2001/XMLSchema#string

Katja Bieber

http://www.w3.org/2001/XMLSchema#string

Michael Kasperkiewicz

http://www.w3.org/2001/XMLSchema#string

Rudolf A Manz

http://www.w3.org/2001/XMLSchema#string

P2860

B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen

The cysteine-rich region of type VII collagen is a cystine knot with a new topology

Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.

Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen

Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa.

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment

Blister-inducing antibodies target multiple epitopes on collagen VII in mice.

Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis

P2888

P304

24-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JID.2015.356

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1079210876

http://www.w3.org/2001/XMLSchema#string

P698

26763420

http://www.w3.org/2001/XMLSchema#string